Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Homogeneous polyporus polysaccharide (HPP) is a purified glucan with an average molecular weight of 6.88 kDa, isolated from the sclerotia of the medicinal mushroom *Polyporus umbellatus*. It functions primarily as an immunomodulator that inhibits the progression of bladder cancer by inducing the polarization of macrophages from the pro-tumor M2 phenotype to the anti-tumor M1 phenotype. This polarization is mediated through the activation of Toll-like receptor 2 (TLR2) and subsequent NF-κB and NLRP3 signaling pathways in macrophages. In the tumor microenvironment, HPP-activated macrophages secrete pro-inflammatory cytokines like IL-1β and TNF-α, which lead to the downregulation of the JAK2/NF-κB signaling pathway in bladder cancer cells, thereby inhibiting their proliferation, migration, and epithelial-mesenchymal transition (EMT) while promoting apoptosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on homogeneous polyporus polysaccharide.